Treatment type: Immunotherapies

  • Kids thank their scientist superheroes amid pandemic

    Olive, 11 and her brother Will, 8 wanted to say a big thank you to their scientist heroes for all their hard work to improve people’s lives, including on COVID-19 research.…  Read more

    Dr Sarah Meachem, COVID19, thank you letters
  • Promising target against Australia’s second deadliest cancer

    Hudson Institute researchers have identified a target for controlling the development of colon cancer that could lead to novel treatment strategies.…  Read more

    Dr Ina Rudloff, Postdoctoral Scientist in the Interventional Immunology in Early Life Diseases Research Group at Hudson Institute
  • All in your genes: new tool investigates on and off switch for genes

    Our genetic material can predispose us to a number of diseases and conditions. Technologies to edit or change our genes are still in their infancy, so scientists are instead looking for ways to use treatments to stop genes that cause health conditions from being turned on.…  Read more

    Professor Paul Hertzog and Dr Jamie Gearing investigating gene pathways at Hudson Institute
  • Could flu deaths be relegated to history?

    A drug used in WW II to treat inflammation may hold the key to saving lives in the fight against flu deaths.…  Read more

  • Mutation offers Holy Grail to combat inflammation

    The discovery of a human mutation that controls inflammation could lead to improved treatments for infectious diseases. Potentially, this could improve health outcomes worldwide for diseases such as bacterial infections, septic shock, or common colds and flu.…  Read more

    Associate Professor Ashley Mansell from the Pattern Recognition Receptors and Inflammation Research Group at Hudson Institute
  • Fielding Foundation awards for researchers

    Hudson Institute’s finest medical researchers will continue to push the boundaries in their field thanks to continued generous support from Mr Peter Fielding and the Fielding Foundation. This year, Research Group Heads, Associate Professor Claudia Nold (2019 Fielding Foundation Fellowship) and Dr Michael Gantier (2019 Fielding Innovation Award), were rewarded for their innovative scientific projects.…  Read more

    Associate Professor Claudia Nold from the Interventional Immunology in Early Life Diseases Research Group at Hudson Institute
  • Lifesaving ‘off-the-shelf’ cancer tracking immunotherapies underway

    ‘Off-the-shelf’ immunotherapies to fight aggressive forms of cancer, including relapsed ovarian and gastric cancers, are being developed in Clayton, Melbourne, thanks to almost $3 million in Federal Government funding awarded to lead participant Cartherics Pty Ltd. Hudson Institute of Medical Research and Monash University researchers are partnering with industry leaders in cell therapies to develop…  Read more

    Professor Alan Trounson
  • New role for cell death-related protein in stomach cancer

    New research from Hudson Institute of Medical Research is showing how a pro-inflammatory protein could offer new hope for stomach cancer treatment. A study, led by Dr Virginie Deswaerte and Professor Brendan Jenkins, found that modifying key components of the inflammatory response in the body could help to prevent tumour growth. The findings have been…  Read more

  • Fighting a deadly pandemic

    Why do seasonal strains of influenza make many people sick yet cause relatively few deaths, while 40 per cent of people affected by strains of avian influenza, or ‘bird flu’, succumb to their infection? A discovery by Associate Professor Ashley Mansell could form a strategy to protect the world’s population from a potential global outbreak…  Read more

  • Could gut bacteria be harnessed to help fight cancer?

    The gut microbiome, the vast ecosystem of bacteria that live within our digestive system, is becoming increasingly recognised for its essential role in supporting our physical and mental health. Now, two new studies from the US are showing that the composition of a patient’s gut bacteria could determine how likely they are to respond to…  Read more